Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Bethlehem, Pennsylvania +2 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Register for Updates
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106
Terminated
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2012
Locations: Lancaster Cancer Center, Ltd., Lancaster, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
NCT00492284
Completed
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/31/2011
Locations: Not set, Philadelphia, Pennsylvania +1 locations
Conditions: Choroidal Neovascularization, Macular Degeneration
Register for Updates
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
NCT00054522
Completed
RATIONALE: Calcitriol may help tumor cells develop into normal cells. Dexamethasone may increase the effectiveness of calcitriol by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining calcitriol with dexamethasone in treating patients with prostate cancer who have undergone surgery or radiation therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/07/2011
Locations: Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
NCT00694135
Completed
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
08/27/2010
Locations: Pennsylvania College of Optometry, Elkins Park, Pennsylvania +1 locations
Conditions: Uveitis, Anterior
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania +2 locations
Conditions: Multiple Myeloma
Register for Updates
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
NCT00835965
Unknown
The combination of aprepitant and lower dose dexamethasone is superior to aprepitant alone with respect to the proportion of patients with a complete response (no vomiting and no use of rescue therapy) during 24 hours after the placement of last suture/staple.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2009
Locations: Lankenau Hospital, Wynnewood, Pennsylvania
Conditions: Nausea, Vomiting
Register for Updates
A Clinical Study of Tobradex AF
NCT00473070
Completed
The purpose of this study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2008
Locations: Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Cataract
Register for Updates